Philippines drug price cuts contested
A new attempt to introduce a price control board for drugs in the Philippines is opposed by the research-based pharmaceutical firms and by the Department of Health, according to local reports. The last attempt to enact legislation designed to cut the price of branded drugs was rejected, because the House of Representatives did not have a quorum to hold a decisive vote (Marketletter March 26).
The new version of the Cheaper Medicines Act, sponsored by Representative Ferjenel Biron (Iloilo), proposes the encouragement of parallel drug imports as well as a price control board. The Philippine Star quotes a Department of Health official as opposing the latter on the grounds that parallel trade will exercise sufficient downward pressure on drugmakers' prices, while a pricing authority would be unwieldy and divided.
PHAP "spent 1B pesos" against parallel drug import law
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze